News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lipocine Inc. (LPCN) Announces Successful Phase 1 Results With LPCN 1107, Potentially The First Oral Product For The Prevention Of Preterm Birth



5/15/2014 11:36:07 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SALT LAKE CITY, May 15, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced the successful completion of a Phase 1 study of LPCN 1107, the company's oral hydroxyprogesterone caproate (HPC) product candidate. The study was designed to determine the pharmacokinetics and bioavailability of LPCN 1107 relative to an intramuscular (IM) HPC, as well as safety and tolerability, in healthy non-pregnant female volunteers. - See more at: http://www.globenewswire.com/news-release/2014/05/15/636804/10081861/en/Lipocine-Announces-Successful-Phase-1-Results-With-LPCN-1107-Potentially-the-First-Oral-Product-for-the-Prevention-of-Preterm-Birth.html#sthash.3VqD75jW.dpuf

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   
Pregnancy

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES